<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>107(2)</volume><submitter>Laakso S</submitter><funding>Intramural NIH HHS</funding><funding>Novo Nordisk Foundation</funding><funding>Helsinki University Hospital</funding><funding>Regional Health Authorities of Western Norway</funding><funding>National Institutes of Health</funding><funding>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</funding><funding>Academy of Finland</funding><funding>Norwegian Research Council</funding><funding>Stiftelsen Kristian Gerhard Jebsen</funding><funding>University of Bergen</funding><funding>Sigrid Jusélius Foundation</funding><funding>Folkhälsan Research Foundation</funding><funding>Foundation for Pediatric Research</funding><pubmed_abstract>&lt;h4>Context&lt;/h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; also known as autoimmune polyendocrine syndrome type 1) has a severe, unpredictable course. Autoimmunity and disease components may affect fertility and predispose to maternal and fetal complications, but pregnancy outcomes remain unknown.&lt;h4>Objective&lt;/h4>To assess fetal and maternal outcomes and course of clinical APECED manifestations during pregnancy in women with APECED.&lt;h4>Design and setting&lt;/h4>A multicenter registry-based study including 5 national patient cohorts.&lt;h4>Patients&lt;/h4>321 females with APECED.&lt;h4>Main outcome measure&lt;/h4>Number of pregnancies, miscarriages, and deliveries.&lt;h4>Results&lt;/h4>Forty-three patients had altogether 83 pregnancies at median age of 27 years (range, 17-39). Sixt</pubmed_abstract><journal>The Journal of clinical endocrinology and metabolism</journal><pagination>e528-e537</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8764323</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Pregnancy Outcome in Women With APECED (APS-1): A Multicenter Study on 43 Females With 83 Pregnancies.</pubmed_title><pmcid>PMC8764323</pmcid><pubmed_authors>Schmitt MM</pubmed_authors><pubmed_authors>Kareva M</pubmed_authors><pubmed_authors>Husebye ES</pubmed_authors><pubmed_authors>Vogt E</pubmed_authors><pubmed_authors>Makitie O</pubmed_authors><pubmed_authors>Betterle C</pubmed_authors><pubmed_authors>Sabbadin C</pubmed_authors><pubmed_authors>Saari V</pubmed_authors><pubmed_authors>Orlova E</pubmed_authors><pubmed_authors>Lionakis MS</pubmed_authors><pubmed_authors>Winer KK</pubmed_authors><pubmed_authors>Laakso S</pubmed_authors><pubmed_authors>Holopainen E</pubmed_authors></additional><is_claimable>false</is_claimable><name>Pregnancy Outcome in Women With APECED (APS-1): A Multicenter Study on 43 Females With 83 Pregnancies.</name><description>&lt;h4>Context&lt;/h4>Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; also known as autoimmune polyendocrine syndrome type 1) has a severe, unpredictable course. Autoimmunity and disease components may affect fertility and predispose to maternal and fetal complications, but pregnancy outcomes remain unknown.&lt;h4>Objective&lt;/h4>To assess fetal and maternal outcomes and course of clinical APECED manifestations during pregnancy in women with APECED.&lt;h4>Design and setting&lt;/h4>A multicenter registry-based study including 5 national patient cohorts.&lt;h4>Patients&lt;/h4>321 females with APECED.&lt;h4>Main outcome measure&lt;/h4>Number of pregnancies, miscarriages, and deliveries.&lt;h4>Results&lt;/h4>Forty-three patients had altogether 83 pregnancies at median age of 27 years (range, 17-39). Sixt</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jan</publication><modification>2025-04-20T03:08:33.543Z</modification><creation>2022-02-11T16:12:01.069Z</creation></dates><accession>S-EPMC8764323</accession><cross_references><pubmed>34570215</pubmed><doi>10.1210/clinem/dgab705</doi></cross_references></HashMap>